Détails du produit
Source
HRP conjugated Monoclonal Anti-MMAE&MMAF Antibody,Mouse IgG1 is a recombinant mouse monoclonal antibody expressed in HEK293 cells.
Antibody Type
Recombinant Monoclonal
Isotype
Mouse IgG1, Kappa
Immunogen
MMAE
Conjugate
HRP Labeled
Specificity
Specifically recognizes the target-MMAE.
Application
ApplicationRecommended UsageELISA1:300-1:3000Purification
Protein A purified / Protein G purified.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
Bioactivity-ELISA

Immobilized Disitamab Vedotin at 1 μg/mL (100 μL/well) can bind HRP conjugated Monoclonal Anti-MMAE&MMAF Antibody,Mouse IgG1 (Cat. No. MME-PLS104) with a linear range of 0.5-16 ng/mL (QC tested).
Protocol
Immobilized Human Her2, His Tag (Cat. No. HE2-H5225) at 1 μg/mL, add Disitamab Vedotin (RC48) in the 100% Human Serum and then add HRP conjugated Monoclonal Anti-MMAE&MMAF Antibody,Mouse IgG1 (Cat. No. MME-PLS104) at 0.5 μg/mL (QC tested).
Protocol
Immobilized Human Her2, His Tag (Cat. No. HE2-H5225) at 1 μg/mL, add Disitamab Vedotin (RC48) in the 0.5% BSA and then add HRP conjugated Monoclonal Anti-MMAE&MMAF Antibody,Mouse IgG1 (Cat. No. MME-PLS104) at 0.5 μg/mL (Routinely tested).
Protocol
Avis des utilisateurs Publier un commentaire




















